$PTP (+2,58 %) Pentixapharm,
What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+9,09 %) was spun off?
Andreas Eckert - founder of Eckert on this:
4 active ingredients including 2 in phase III and 2 in I/IIa
Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.
However, further financing measures are required here.
20.8 million shares + 3.9 million in free float.
Other competitors in the market are
Telix Pharma and $TLX (+1,79 %)
Lantheus Holding $LNTH (+3,77 %)
